European Heart Journal

• 

  Publication Venue For

  • 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC..  42:373-498. 2021
  • Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial..  38:2813-2822. 2017
  • The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial..  37:3576-3584. 2016
  • Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease..  37:1993-2001. 2016
  • Lessons learned and a look to the future: The chronic ischemic heart disease (CICD) pilot registry.  37:161-163. 2016
  • Current worldwide nuclear cardiology practices andradiationexposure: Results from the 65country IAEA nuclear cardiology protocols cross-sectional study (INCAPS).  36:1689-1696. 2015
  • Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial.  36:288-296. 2015
  • Prognostic implication of the new peri-PCI (type 4a) myocardial infarction definition according to the third universal definition of myocardial infarction in patients with NSTE ACS.  35:138-138. 2014
  • Relationship between diabetes, race, obesity and outcomes in patients with acute coronary syndrome: a pool analysis from randomized trials.  34:787-787. 2013
  • Contributions of peak expiratory flow to assessment of acute decompensated heart failure: insights from ASCEND-HF.  32:964-964. 2011
  • Gender paradox: higher incidence but lower one-year mortality with bleeding among women compared with men following fibrinolysis for acute ST-elevation myocardial infarction.  32:166-166. 2011
  • The independent prognostic value of hyponatremia in a cohort of heart failure patients: analysis from the Duke databank for cardiovascular disease.  32:134-134. 2011
  • Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada: insights from the APEX-AMI trial.  32:872-872. 2011
  • Prognostic utility of quantifying evolutionary ST-segment depression on early follow-up electrocardiogram in patients with non-ST-segment elevation acute coronary syndromes..  31:958-966. 2010
  • Early in-ospital worsening heart failure predicts adverse outcome in patients.  30:719-719. 2009
  • Echocardiographic predictors of long-term survival in adults with pulmonary hypertension.  30:115-115. 2009
  • Effects of the new vasodilator relaxin for the treatment of patients with acute heart failure and normal to elevated blood pressure: results of a phase 2b study (Pre-RELAX-AHF).  30:424-425. 2009
  • Impact of anemia in patients with pulmonary hypertension.  30:260-260. 2009
  • Impact of incidentally discovered patent foramen ovale and its operative repair on long-term survival.  30:6-6. 2009
  • Improved pulmonary insufficiency with inhaled vasodilator assessed by cardiac magnetic resonance imaging.  30:811-811. 2009
  • Increased symptom-improvement with the novel vasodilator, relaxin, in Acute Heart Failure (AHF) patients with elevated blood pressure. Results from the Pre-RELAX-AHF study.  30:164-164. 2009
  • Novel intravascular defibrillator (InnerPulse PICD): defibrillation thresholds of PICD compared to Medtronic ICD in a canine model.  30:276-276. 2009
  • Patient-reported dyspnea in acute heart failure trials. Use of the Likert and the visual analog scales in the pre-RELAX AHF study.  30:445-446. 2009
  • Prevalence & prognostic importance of micro-& macro-albuminuria in heart failure- an analysis from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Programme.  30:876-876. 2009
  • Pulmonary vasodilator challenge predicts survival in patients with various etiologies of pulmonary hypertension.  30:899-900. 2009
  • Racial disparities in survival in patients with pulmonary hypertension.  30:513-513. 2009
  • Time to treatment and vasodilator efficacy in acute heart failure: Results from the Pre-RELAX-AHF study.  30:424-424. 2009
  • Worsening renal function in acute heart failure: change in BP and effects of relaxin.  30:1020-1021. 2009
  • Acute severe hypertension has high morbidity, mortality, and readmission rates: results from the STAT registry.  29:513-513. 2008
  • An RNA aptamer inhibiting factor IXa and its complementary oligonucleotide antidote.  29:328-328. 2008
  • Cognitive function and anticoagulation control in patients with atrial fibrillation.  29:258-258. 2008
  • Endoscopic vein harvesting is a strong independent predictor of vein graft failure in patients undergoing coronary artery bypass graft surgery.  29:284-285. 2008
  • Has the frequency of bleeding improved over time for patients presenting with an acute coronary syndrome? The GRACE Registry.  29:326-326. 2008
  • Impact of incidentally discovered patent foramen ovale and its repair on perioperative outcomes in 13,260 cardiothoracic surgery patients.  29:124-124. 2008
  • Late recanalization of infarct related artery has no impact on clinical outcomes regardless of ejection fraction: Results from the Occluded Artery Trial (OAT).  29:679-679. 2008
  • Mechanical complications are uncommon in STEMI treated with primary-PCI: insights from APEX-AMI.  29:137-138. 2008
  • Mortality after cardiogenic shock remains high in ST-elevation myocardial infarction treated with primary PCI: insights from APEX AMI.  29:447-447. 2008
  • Prevalence and predictors of dyssynchrony as determined by gated SPECT perfusion imaging in patients with left ventricular dysfunction.  29:5-5. 2008
  • Surgical treatment of anomalous coronary arteries passing between the great vessels in older adults may not improve survival.  29:7-7. 2008
  • Triple combination Ezetimibe/Simvastatin plus extended release Niacin therapy improves ratios of ApoB/ApoA-I containing lipoproteins in hyperlipidemia patients.  29:345-346. 2008
  • Impact of home warfarin use on treatment patterns and bleeding complications for patients with non-ST-segment elevation acute coronary syndromes: observations from the CRUSADE quality improvement initiative..  29:1103-1109. 2008
  • Reperfusion after primary angioplasty for ST-elevation myocardial infarction: predictors of success and relationship to clinical outcomes in the APEX-AMI angiographic study..  29:1127-1135. 2008
  • Adverse outcomes in fibrinolytic-based facilitated percutaneous coronary intervention: insights from the ASSENT-4 PCI electrocardiographic substudy..  29:871-879. 2008
  • Variation in the use of stress testing and outcomes in patients with non-ST-elevation acute coronary syndromes: insights from GUSTO IIb..  29:880-887. 2008
  • Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study..  29:748-756. 2008
  • Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go..  29:609-617. 2008
  • Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment..  29:315-323. 2008
  • Failure of investigator adherence to electrocardiographic entry criteria is frequent and influences clinical outcomes: lessons from APEX-AMI..  28:2850-2857. 2007
  • Cardiovascular disease on a global scale: defining the path forward for research and practice..  28:2678-2684. 2007
  • A new model for predicting mortality in acute ST elevation myocardial infarction treated with primary PCI: results from the APEX AMI trial.  28:59-59. 2007
  • Adverse outcomes in fibrinolytic-based facilitated PCI: insights from the ASSENT-4 PCI electrocardiographic substudy.  28:59-59. 2007
  • Atrial fibrillation is associated with worse outcomes in ST elevation and non ST elevation acute coronary syndromes.  28:259-260. 2007
  • Bleeding risk of Glycoprotein (GP) IIb IIIa inhibitors or thienopyridines with fondaparinux vs. enoxaparin in Acute Coronary Syndromes: insights from the OASIS 5 trial.  28:516-516. 2007
  • Can we predict non-fatal cardiovascular events in acute coronary syndrome? The Global Registry of Acute Coronary Events.  28:689-689. 2007
  • Comparison of outcomes between patients undergoing percutaneous coronary stent implantation with eptifibatide and abciximab: an analysis using propensity score methods.  28:184-184. 2007
  • Electrocardiographic left ventricular hypertrophy in GUSTO IV ACS: an important risk marker of mortality in women..  28:2064-2069. 2007
  • Outcomes for stenting in single and multivessel coronary artery disease using established and novel paclitaxel eluting stent platforms: COSTAR II.  28:577-577. 2007
  • Predictors of angiographic success and relationship to clinical outcomes during primary PCI for ST elevation acute myocardial infarction: insights from APEX-AMI.  28:660-660. 2007
  • Short-term outcomes are at least as good with drug eluting vs. bare metal stents: insights from APEX AMI.  28:9-9. 2007
  • Similar association between age and outcomes in high-risk ACS patients treated with enoxaparin or unfractionated heparin.  28:218-218. 2007
  • The effect of duration of therapy on the benefit of fondaparinux over enoxaparin in acute coronary syndromes: insights from the OASIS 5 trial.  28:187-187. 2007
  • Why did pexelizumab fail to benefit acute myocardial infarction (STEMI) patients undergoing primary PCI? Insights into the role of inflammation and immunity and the complement inhibitor pexelizumab.  28:384-385. 2007
  • Retinal vessel diameter and cardiovascular mortality: pooled data analysis from two older populations..  28:1984-1992. 2007
  • Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes..  28:1598-1660. 2007
  • Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction..  28:1709-1716. 2007
  • Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes..  28:1193-1204. 2007
  • Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study..  28:1109-1116. 2007
  • Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trial..  28:1079-1084. 2007
  • Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry..  28:980-988. 2007
  • Predictors of stroke in high-risk patients after acute myocardial infarction: insights from the VALIANT Trial..  28:685-691. 2007
  • Ruminating on OAT: is the case closed?.  28:531-532. 2007
  • The cost of implantable defibrillators: how the perception of reality depends on perspective.  28:386-387. 2007
  • Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials..  28:425-432. 2007
  • The high cost of implantable defibrillators..  28:388-391. 2007
  • The impact of anthropomorphic indices on clinical outcomes in patients with acute ST-elevation myocardial infarction..  28:415-424. 2007
  • Diabetes mellitus and insulin therapy in infective endocarditis..  28:3-4. 2007
  • Electrical storm in patients with an implantable defibrillator: incidence, features, and preventive therapy: insights from a randomized trial..  27:3027-3032. 2006
  • Increased mortality after implantation of first generation drug-eluting stents: seeing the smoke, where is the fire?.  27:2737-2739. 2006
  • Predictors of stroke within 30 days in patients with non-ST-segment elevation acute coronary syndromes..  27:2956-2961. 2006
  • Results of the first clinical study of adjunctive CAldaret (MCC-135) in patients undergoing primary percutaneous coronary intervention for ST-Elevation Myocardial Infarction: the randomized multicentre CASTEMI study..  27:2516-2523. 2006
  • Glucose, insulin, and acute myocardial infarction: Reply [4].  27:2142-2143. 2006
  • A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study..  27:1530-1538. 2006
  • International variation in invasive care of the elderly with acute coronary syndromes..  27:1558-1564. 2006
  • Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study..  27:1289-1297. 2006
  • Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme..  27:1447-1458. 2006
  • Optimizing use of revascularization and clinical outcomes in ST-elevation myocardial infarction: insights from the GUSTO-V trial..  27:1198-1206. 2006
  • Persistent and reversible cardiac dysfunction among amateur marathon runners..  27:1079-1084. 2006
  • Aborted myocardial infarction: a new target for reperfusion therapy..  27:901-904. 2006
  • Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomes..  27:527-533. 2006
  • Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarction..  27:419-426. 2006
  • How many patients with heart failure are eligible for cardiac resynchronization? Insights from two prospective cohorts..  27:323-329. 2006
  • Predictors of mortality and morbidity in patients with chronic heart failure..  27:65-75. 2006
  • Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention..  26:2396-2403. 2005
  • Extent of ST-segment depression and cardiac events in non-ST-segment elevation acute coronary syndromes..  26:2106-2113. 2005
  • Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry..  26:2114-2119. 2005
  • Moving proximally through the intersection between the process and the content of care in ST-elevation myocardial infarction..  26:1937-1938. 2005
  • Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial..  26:1964-1970. 2005
  • A dynamic model forecasting myocardial infarct size before, during, and after reperfusion therapy: an ASSENT-2 ECG/VCG substudy..  26:1726-1733. 2005
  • Simplifying risk stratification in non-ST-segment elevation acute coronary syndromes.  26:431-431. 2005
  • Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies..  26:1461-1474. 2005
  • Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial..  26:1506-1512. 2005
  • Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry..  26:1063-1069. 2005
  • The effect of intra-aortic balloon counterpulsation on left ventricular functional recovery early after acute myocardial infarction: a randomized experimental magnetic resonance imaging study..  26:1235-1241. 2005
  • Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction..  26:667-674. 2005
  • The investigation of biomarkers in cardiovascular disease: time for a coordinated, international effort..  26:421-422. 2005
  • Aorto-cavitary fistulous tract formation in infective endocarditis: clinical and echocardiographic features of 76 cases and risk factors for mortality..  26:288-297. 2005
  • Assessing risk in FRISC..  26:103-104. 2005
  • Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials..  26:128-136. 2005
  • An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry..  25:1911-1919. 2004
  • Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme..  25:1920-1926. 2004
  • Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial..  25:1688-1694. 2004
  • Association of revascularisation with low mortality in non-ST elevation acute coronary syndrome, a report from GUSTO IV-ACS..  25:1494-1501. 2004
  • Persistent diastolic dysfunction despite complete systolic functional recovery after reperfused acute myocardial infarction demonstrated by tagged magnetic resonance imaging..  25:1419-1427. 2004
  • Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes..  25:313-321. 2004
  • International variation in the use of evidence-based medicines for acute coronary syndromes..  24:2133-2141. 2003
  • Intra-aortic balloon counterpulsation in US and non-US centres: results of the Benchmark Registry..  24:1763-1770. 2003
  • Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trial..  24:1807-1814. 2003
  • Early hospital discharge after uncomplicated myocardial infarction: are further improvements possible?.  24:1613-1615. 2003
  • International differences in in-hospital revascularization and outcomes following acute myocardial infarction: a multilevel analysis of patients in ASSENT-2..  24:1640-1650. 2003
  • From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE)..  24:1414-1424. 2003
  • ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction..  24:1515-1522. 2003
  • The impact of gender on the treatment and outcomes of patients with early reinfarction after fibrinolysis: insights from ASSENT-2..  24:1024-1034. 2003
  • Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study..  24:897-908. 2003
  • Does the discharge ECG provide additional prognostic insight(s) in non-ST elevation ACS patients from that acquired on admission?.  24:522-531. 2003
  • P2275 Plasma homocystein levels independently correlate with angiographic extension of coronary artery disease.  24:436-436. 2003
  • Cardiac markers in acute coronary syndromes-refining our knowledge..  24:136-137. 2003
  • Predictors of 90-day outcome in patients stabilized after acute coronary syndromes..  24:172-181. 2003
  • Time-based risk assessment after myocardial infarction. Implications for timing of discharge and applications to medical decision-making..  24:182-189. 2003
  • Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes..  23:1538-1545. 2002
  • Slowed ST segment recovery despite early infarct artery patency in patients with Q waves at presentation with a first acute myocardial infarction. Implications of initial Q waves on myocyte reperfusion..  23:1449-1455. 2002
  • Determinants of matrix metalloproteinases plasma concentration and activity in premature coronary atherosclerosis.  23:135-135. 2002
  • Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes; the GUSTO-IIb haemostasis substudy..  23:1202-1212. 2002
  • Effect of simvastatin on endothelial damage markers and clinical outcomes in acute coronary syndromes.  23:419-419. 2002
  • Does eptifibatide confer a greater benefit to patients with unstable angina than with non-ST segment elevation myocardial infarction? Insights from the PURSUIT Trial..  23:1102-1111. 2002
  • Assessment of myocardial viability by cardiovascular magnetic resonance imaging..  23:602-619. 2002
  • Clinical characteristics and outcome of patients with early (<2 h), intermediate (2-4 h) and late (>4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction..  23:550-557. 2002
  • Early invasive strategy for acute coronary syndromes without persistent ST-segment elevation: has the time come for 'drive-through' angiography?.  23:191-194. 2002
  • Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker..  23:239-246. 2002
  • Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA..  22:2253-2261. 2001
  • ESPRIT in context: pharmacology matters!.  22:1965-1967. 2001
  • Baseline characteristics that identify patients at high risk of death following myocardial infarction. Preliminary findings from the ALIVE trial.  22:700-700. 2001
  • Body mass index remains a significant predictor of outcome after percutaneous coronary interventions in the era of IIbIIIa inhibition.  22:524-524. 2001
  • Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study..  22:1601-1612. 2001
  • Eptifibatide (Integrilin (R)) in coronary stent implantation: long-term results of the ESPRIT trial.  22:121-121. 2001
  • Genetic variation in human Stromelysin-1 and Gelatinase B genes and acute coronary syndromes in young males.  22:164-164. 2001
  • Increased rates of stent thrombosis among patients with acute coronary syndromes: insights from two large oral IIb/IIIa antagonist trials.  22:385-385. 2001
  • Low heart rate variability (triangular index method) predicts mortality independent of beta-blocker usage, LVEF, and other factors: ALIVE trial early findings.  22:701-701. 2001
  • Pharmacokinetic and pharmacodynamic responses of the novel factor Xa inhibitor DX-9065a: results from the Xa neutralization for atherosclerotic disease understanding (XaNADU) IB trial.  22:664-+. 2001
  • The ALIVE study: heart rate variability prospectively identifies patients at high risk of death after myocardial infarction.  22:696-+. 2001
  • Aortic stiffness and calcification..  22:181. 2001
  • Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial..  21:1967-1978. 2000
  • Lack of progress in cardiogenic shock: lessons from the GUSTO trials..  21:1928-1936. 2000
  • Reperfusion synergism: will it be both sustained and safe?.  21:1913-1916. 2000
  • Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators..  21:1750-1758. 2000
  • Electron beam computed tomography: on its way into mainstream cardiology?.  21:1556-1557. 2000
  • Inter-regional differences in acute coronary syndrome trials..  21:1397-1399. 2000
  • Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction..  21:1502-1513. 2000
  • National and regional registries: what good are they?.  21:1401-1403. 2000
  • Educational level and 30-day mortality after acute myocardial infarction: results from the GUSTO III trial.  21:223-223. 2000
  • Social isolation and 30-day mortality after acute myocardial infarction: results from the GUSTO III trial.  21:213-213. 2000
  • The level of platelet inhibition maintained with a GPIIb/IIIa inhibitor following coronary intervention is strongly associated with the risk of a post-procedural MACE: results of the GOLD study.  21:145-145. 2000
  • Use of a near-patient, whole blood, multi-marker strategy (MMS) for evaluation of patients with chest pain: Results of the CHECKMATE study.  21:19-19. 2000
  • Troponins in pericarditis: implications for diagnosis and management of chest pains patients..  21:798-800. 2000
  • American College of Cardiology/ European Society of Cardiology international study of angiographic data compression phase I. The effects of lossy data compression on recognition of diagnostic features in digital coronary angiography..  21:668-678. 2000
  • Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT..  21:371-381. 2000
  • Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry..  20:1182-1190. 1999
  • Minimal myocardial damage during coronary intervention is associated with impaired outcome..  20:1112-1119. 1999
  • Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Global Use of Strategies to Open Occluded Coronary Arteries..  20:128-135. 1999
  • Improved outlook for patients with acute myocardial infarction: an interim progress report..  19:1416-1418. 1998
  • Mechanism of protective effects of ACE inhibition on coronary artery disease..  19 Suppl J:J2-J6. 1998
  • Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes..  19 Suppl D:D22-D30. 1998
  • International roundtable on Use of GP IIb/IIIa inhibitors in coronary syndromes: State of the art, Davos, Switzerland, 15-16 February 1997: Foreward.  19. 1998
  • The GUSTO trial and the open artery theory..  18 Suppl F:F2-10. 1997
  • Nebulized prostacyclin for pulmonary hypertension: a step in the right direction..  18:1364-1365. 1997
  • Selection of reperfusion therapy for individual patients with evolving myocardial infarction..  18:1371-1381. 1997
  • Predictors of outcome of reperfusion therapy..  18:728-735. 1997
  • Pragmatic and mechanistic trials..  18:367-370. 1997
  • The rationale for thrombolytic therapy..  17 Suppl E:2-8. 1996
  • Differential expression of angiotensin receptor subtypes in the myocardium: a hypothesis..  17:978-980. 1996
  • Non-invasive prediction of reperfusion and coronary artery patency by continuous ST segment monitoring in the GUSTO-I trial..  17:689-698. 1996
  • Serum myoglobin for the early non-invasive detection of coronary reperfusion in patients with acute myocardial infarction..  17:399-406. 1996
  • Erratum: Non-invasive prediction of reperfusion and coronary artery patency by continuous ST segment monitoring in the GUSTO-I trial (European Heart Journal (1996) 17 (689-698)).  17:1451. 1996
  • An overview of the results of the EPIC trial..  16 Suppl L:43-49. 1995
  • Early clinical experience with integrelin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptor..  16 Suppl L:50-55. 1995
  • Progress culminating from ten years of clinical trials on thrombolysis for acute myocardial infarction. GUSTO-I Steering Committee. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries..  16:1024-1026. 1995
  • Impact of infarct artery patency on the relationship between electrocardiographic and ventriculographic evidence of acute myocardial ischaemia..  15:1356-1361. 1994
  • Extracellular lipid deposition in atherosclerosis..  11 Suppl E:20-28. 1990
  • Emerging role of the tissue renin-angiotensin systems in congestive heart failure..  11 Suppl B:65-71. 1990
  • In vitro analysis of jets by Doppler colour flow imaging: the importance of time to maximum jet area..  11:361-367. 1990
  • Left ventricular outflow acceleration in dilated cardiomyopathy its relationship with intrinsic ventricular load dynamics.  11:427-427. 1990
  • New interventional technology for the management of multivessel coronary artery disease..  10 Suppl H:52-56. 1989
  • Heart rate and metabolic response to competitive squash in veteran players: identification of risk factors for sudden cardiac death..  10:1029-1035. 1989
  • Two-dimensional echocardiography in arrhythmogenic right ventricular dysplasia..  10 Suppl D:22-26. 1989
  • Vascular and renal prostaglandins as counter-regulatory systems in heart failure..  9 Suppl H:15-19. 1988
  • Spontaneously healing infective endocarditis: An unrecognized phenomenon?.  8:327-330. 1987
  • Guidelines for exercise therapy of the elderly after myocardial infarction..  5 Suppl E:121-123. 1984
  • The value of early out-patient cardiac exercise programmes for the elderly in comparison with other selected age groups..  5 Suppl E:113-115. 1984
  • Imaging approach to the assessment of cardiomyopathies using delayed enhancement cardiovascular magnetic resonance: reply.  26:2602-2602.
  • Choice of P2Y12 inhibitor and clinical outcomes in the AUGUSTUS study: support for an individualised approach 2020
  • Combination of fondaparinux with radial access is associated with low rates of in-hospital MACE and major bleeding events in patients with acute coronary syndrome 2020
  • Impact of treatment strategies for AF on the progression and regression of AF type in the CABANA trial 2020
  • Incidence and risk of short episodes of atrial fibrillation detected with 14 days of continuous electrocardiographic monitoring 2020
  • Pharmacokinetics of apixaban in patients with end stage renal disease on hemodialysis and atrial fibrillation: results from the RENAL-AF trial 2020
  • Safety and efficacy of antithrombotic therapy according to stroke and bleeding risk in patients with atrial fibrillation and acute coronary syndrome or PCI: insights from AUGUSTUS 2020
  • Apixaban 2.5 mg twice daily is effective and safe for patients with atrial fibrillation and combinations of advanced age, low body weight, and elevated creatinine: insights from ARISTOTLE 2019
  • Association of ceramide and phospholipid levels and cardiovascular events in stable coronary heart disease: findings from the STABILITY Biomarkers substudy 2019
  • Baseline characteristics, healthcare resource use and clinical outcomes of stable post-myocardial infarction patients with diabetes: insights from the global prospective TIGRIS study 2019
  • Effect of hypertension and systolic blood pressure on cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: the EUCLID trial 2019
  • Efficacy of alirocumab treatment after acute coronary syndrome according to new ACC/AHA guidelines for lipid-lowering therapy 2019
  • Impact of AF type on the outcome of atrial fibrillation ablation: insights from the CABANA trial 2019
  • Impact of different estimates of renal function on cardiovascular mortality and major bleeding in patients with atrial fibrillation on oral anticoagulation 2019
  • Lipoprotein subclasses associated with high-risk coronary atherosclerotic plaque: insights from the PROMISE clinical trial 2019
  • Long-term safety and effectiveness of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients (pts): update from PIONEER open-label extension (PIONEER-OLE) study 2019
  • Network characteristics of a hypertension referral system in western kenya 2019
  • Older patients with atrial fibrillation and comorbidities are less likely to be treated with oral anticoagulation: insights from a nationwide study 2019
  • Outcomes of catheter ablation for atrial fibrillation based on sex: data from the cabana trial 2019
  • Patients explanations of self-care in chronic heart failure: a grounded theory analysis of qualitative data from PANACEA-HF Phase 1 2019
  • Predictors of DAPT use in patients beyond 1 year post myocardial infarction: Insights from the TIGRIS observational study 2019
  • Predictors of atrial fibrillation in patients with embolic stroke of undetermined source: an analysis of the RE-SPECT ESUS trial 2019
  • Risk of stroke in hypertensive patients with atrial fibrillation treated with oral anticoagulants 2019
  • Triple vs. double antithrombotic therapy in patients needing oral anticoagulation undergoing percutaneous coronary intervention: a meta-analysis 2019
  • Agent Orange exposure in veterans with heart failure 2018
  • Association of hepatic steatosis with adverse cardiovascular events: insights from the PROspective Multicenter Imaging Study for Evaluation of chest pain (PROMISE) trial 2018
  • Association of low hemoglobin with venous thromboembolism in acutely ill hospitalized medical patients: findings from the APEX trial 2018
  • Association of renin-angiotensin system inhibition with clinical outcomes in patients undergoing transcatheter aortic valve replacement: analysis from the STS/ACC TVT Registry 2018
  • Asymptomatic deep vein thrombosis in acutely ill medical patients: insights from the APEX trial 2018
  • Betrixaban compared to enoxaparin among obese acute medically ill subjects: an APEX trial subgroup analysis 2018
  • Betrixaban versus enoxaparin for venous thromboembolism prophylaxis in critically ill patients: findings from the APEX trial 2018
  • Can biomarkers be used to predict cardiopulmonary exercise test performance in patients with chronic heart failure? 2018
  • Cardiac troponin T concentrations are lower in women than men with atrial fibrillation but have similar prognostic value regardless of sex - insights from the ARISTOTLE trial 2018
  • Characterization of major and clinically relevant non-major bleeding in the APEX trial 2018
  • Cluster analysis of cardiovascular risk phenotypes in patients with type 2 diabetes and established atherosclerotic cardiovascular disease: a potential approach to precision medicine 2018
  • Diamond and Forrester-predicted vs. coronary CTA-observed prevalence of obstructive CAD in patients with stable chest pain: results from the PROMISE trial 2018
  • Effects of once-weekly exenatide on clinical outcomes in the subgroup of patients with pre-existing cardiovascular disease: insights from EXSCEL 2018
  • Elevated biomarkers are associated with increased risk of death and heart failure hospitalization in patients with atrial fibrillation: insights from the ARISTOTLE trial 2018
  • Faster heart rate is associated with significantly higher risk of death and hospitalization due to heart failure in patients with persistent or permanent atrial fibrillation: insights from ARISTOTLE 2018
  • LDL-C treatment patterns and associated outcomes in patients with type 2 diabetes and CVD: insights from TECOS 2018
  • Linear ongoing risk of major cardiovascular events in a global prospective registry of high-risk patients with stable coronary disease: insights from the TIGRIS study 2018
  • Moderate to severe renal insufficiency and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: the EUCLID trial 2018
  • Novel prognostic biomarkers identified by proximity extension assay are associated with major bleeding in patients with atrial fibrillation on oral anticoagulation: insights from the ARISTOTLE trial 2018
  • Performance of a machine learning model vs. IMPROVE score for VTE prediction in acute medically ill patients: insights from the APEX trial 2018
  • Use of oral anticoagulation is less among hospitalized patients with paroxysmal compared to persistent or permanent atrial fibrillation 2018
  • A novel biomarker-based risk score to predict death in patients with atrial fibrillation: Insights from the ARISTOTLE and RE-LY trials 2017
  • Association between the timing of surgery for complicated infective endocarditis and survival 2017
  • Clinical outcomes in patients with atrial fibrillation and echocardiographic risk factors for stroke anticoagulated with apixaban or warfarin 2017
  • Determinants of antithrombotic treatment of patients with AF: baseline characteristics from a clustered randomized trial to IMProve treatment with AntiCoagulanTs in patients with AF (IMPACT-AF) 2017
  • Diabetes and cardiovascular risk in patients with symptomatic peripheral artery disease 2017
  • Extended duration betrixaban in acutely ill medical patients is associated with reduction in fatal or irreversible ischemic or bleeding events compared with standard dose enoxaparin: an APEX substudy 2017
  • INR prior to bleeding is below 3.0 most of the time in patients with atrial fibrillation using warfarin 2017
  • Low apolipoprotein a1 is significantly associated with decreased risk of cardiovascular events in anticoagulated patients with atrial fibrillation: insights from the ARISTOTLE trial 2017
  • Relationships between cigarette smoking, infarct size, and clinical outcomes in patients undergoing primary PCI For STEMI: a patient-level pooled analysis of 10 randomized trials 2017
  • Serial IL-6 levels and risk of death in anticoagulated patients with atrial fibrillation: Insights from the ARISTOTLE trial 2017
  • The association between obesity, diabetes control, and cardiovascular outcomes: insights from the TECOS trial 2017
  • The occurrence of stroke and TIA in patients with peripheral artery disease and the effect of ticagrelor versus clopidogrel in EUCLID 2017
  • Ticagrelor in patients with symptomatic peripheral artery disease and prior coronary artery disease 2017
  • Women with stable coronary artery disease have better clinical outcomes than men, but this association is modified by degree of depression: insights from the STABILITY trial 2017
  • A multi-time-point based multimarker risk stratification strategy in acute heart failure - results from the RELAX-AHF trial 2016
  • Comparing novel biomarkers associated with heart failure preserved ejection fraction (HFpEF): A matched case-control analysis 2016
  • Longer-term oral antiplatelet use in stable post-MI patients: Insights from the TIGRIS study 2016
  • Mechanisms and impact on cardiac mortality of right ventricular dysfunction in non-ischaemic cardiomyopathy 2016
  • Multinational ethnic variations in self-reported health status in chronic heart failure patients 2016
  • Net clinical benefit of rivaroxaban compared with warfarin in patients with atrial fibrillation 2016
  • Patients with atrial fibrillation and history of falls are at high risk for bleeding but have less bleeding with apixaban than warfarin: results from the ARISTOTLE trial 2016
  • Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT AF) 2016
  • Pharmacotherapy for atrial fibrillation in patients with chronic kidney disease: insights from the outcomes registry for better informed treatment of atrial fibrillation (ORBIT AF) 2016
  • Plasma amino acid concentrations are independently associated with adverse outcomes in heart failure and preserved ejection fraction: prognostic utility of amino acid profiles in HFpEF 2016
  • Prognostic Utility of GDF-15 in Chronic Heart Failure: Insights From the HF-ACTION Study 2016
  • Systemic embolization in patients with atrial fibrillation: results from ROCKET AF 2016
  • The EVEREST II REALISM Continued Access Study-1 year outcomes in patients with functional mitral regurgitation reported by baseline New York Heart Association functional class 2016
  • Biomarker-based risk score for prediction of cardiovascular events in stable coronary heart disease - Experiences from the STABILITY biomarker substudy 2015
  • Characterization of cardiovascular endpoints, impact of event adjudication and effects of darapladib in the STABILITY trial 2015
  • Digoxin use is associated with higher mortality among patients with atrial fibrillation with and without heart failure: insights from the ARISTOTLE trial 2015
  • Effect of ivabradine on heart rate variability in patients with stable coronary artery disease 2015
  • Efficacy and safety of apixaban compared with warfarin in relation to renal function over time in patients with atrial fibrillation: Insights from the ARISTOTLE trial 2015
  • External validation of the biomarker-based ABC-stroke risk score for atrial fibrillation 2015
  • Hypotension in patients with acute heart failure: Insights from RELAX-AHF 2015
  • Impact of pulmonary hypertension on mortality in patients treated with nitric oxide for failure to wean following cardiothoracic surgery 2015
  • Improved survival after out-of-hospital cardiac arrest most substantial in younger patients - results from a statewide quality improvement initiative in North Carolina during 2010-2013 2015
  • Initial experience with idarucizumab in dabigatran-treated patients requiring emergency surgery or interventon: interim results from the RE-VERSE AD study 2015
  • Less non-major bleeding with apixaban versus warfarin among patients with atrial fibrillation: insights from the ARISTOTLE trial 2015
  • Management and clinical consequences of major bleeding in high-risk patients following an acute coronary syndrome. Is aspirin the problem? Insights from the APPRAISE-2 trial 2015
  • Off-hours versus regular hours admission and its relation with long-term mortality of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention 2015
  • Outcomes of rivaroxaban versus warfarin in women and men with nonvalvular atrial fibrillation: results from the ROCKET AF trial 2015
  • Rivaroxaban vs. warfarin with concomitant aspirin use in patients with atrial fibrillation: findings from the ROCKET AF trial 2015
  • Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for novel oral anticoagulant dose adjustment 2015
  • Stroke and bleeding outcomes with apixaban versus warfarin in patients with high creatinine, low body weight or high age receiving standard dose apixaban for stroke prevention in atrial fibrillation 2015
  • Survival improved for men but not women, despite increased bystander CPR and first resonder defibrillation for both: results form a statewide quality improvement initiative 2015
  • The EVEREST II REALISM Continued Access study-1 year outcomes in patients with primary mitral regurgitation 2015
  • The evolution of ICD programming practice: What is the relative impact of clinical evidence on clinical practice? 2015
  • Treatment consistency across levels of baseline renal function with rivaroxaban compared with warfarin: insights from ROCKET AF 2015
  • A new biomarker based risk score for predicting major bleeding in atrial fibrillation - the ABC (age, biomarkers, current disease) risk score 2014
  • Digoxin use in patients with atrial fibrillation is associated with adverse cardiac outcomes: results from the ROCKET AF trial 2014
  • Efficacy and safety of ticagrelor in patients with acute coronary syndrome and heart failure - insights from the platelet inhibition and patient outcomes (PLATO) trial 2014
  • Galectin-3 is associated with worse clinical outcome in patients with atrial fibrillation: A substudy from the ARISTOTLE trial 2014
  • Impact of early initiation of intravenous prostanoid therapy in patients with congenital heart disease-related pulmonary arterial hypertension 2014
  • Impact of insurance status on survival in pulmonary hypertension 2014
  • Incidence and impact of patent foramen ovale among patients with pulmonary hypertension 2014
  • Interleukin-6 and C-reactive protein and risk for cardiovascular events and death in anticoagulated patients with atrial fibrillation 2014
  • Patients with native aortic stenosis represent a high-risk subgroup in nonvalvular atrial fibrillation - Results from ROCKET AF 2014
  • Predictors of and clinical outcomes after internal mammary artery graft failure: insights from the PREVENT-IV trial 2014
  • Relationship between troponin levels and long-term outcomes in medically managed patients with non-ST-segment elevation acute coronary syndromes: insights from the TRILOGY ACS trial 2014
  • The efficacy of apixaban compared to warfarin in patients with atrial fibrillation with high coagulation activity despite anticoagulant treatment 2014
  • A composite peripheral blood gene expression score has high sensitivity for obstructive coronary artery disease in a non-invasive imaging population and correlates with plaque burden and morphology by 2013
  • A systematic review of outcomes related to hybrid coronary revascularization in patients with multi-vessel coronary artery disease in the drug-eluting stent era 2013
  • ADMA and SDMA predict outcomes in patients with chronic atrial fibrillation: an ARISTOTLE substudy 2013
  • Association between type of valve prosthesis and one year mortality in IE: an analysis of 1467 patients from the International collaboration on endocarditis prospective cohort study 2013
  • International variation in management and outcomes in high-risk patients following acute coronary syndromes: results from the APPRAISE-2 trial 2013
  • Mechanical dyssynchrony defined by phase analysis from GSPECT: Does it predict all cause and cardiovascular mortality? 2013
  • Reperfusion arrhythmia bursts predict larger infarct size in STEMI patients undergoing primary percutaneous coronary intervention despite optimal epicardial and microvascular flow 2013
  • Risk of events in the 30 days following a major bleed with Apixaban or Warfarin - experiences from the ARISTOTLE trial 2013
  • Use of apixaban and warfarin in patients undergoing invasive procedures: insights from ARISTOTLE 2013
  • Ventricular arrhythmia bursts following primary percutaneous coronary intervention for acute myocardial infarction: correlations with microvascular obstruction and final infarct size using CMR 2013
  • Apixaban after acute coronary syndrome in patients with heart failure: insights from the APPRAISE-2 trial 2012
  • Baseline hemoglobin predicts post-discharge events in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial 2012
  • Effect of apixaban on all-cause mortality in atrial fibrillation: an imputed placebo analysis 2012
  • Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia 2012
  • Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial 2012
  • Hemodynamic response to hypoxia in heart failure patients with high peripheral chemosensitivity 2012
  • Inadequate anticoagulant therapy during end of study transition to open-label vitamin K antagonist therapy: experience in ROCKET AF 2012
  • Increased levels of D-dimer identify patients with atrial fibrillation at high risk for bleeding an ARISTOTLE substudy 2012
  • Increased levels of D-dimer in atrial fibrillation identify patients with higher risk of thromboembolic events and death 2012
  • Ischemia change in heart failure patients with stable coronary artery disease is an independent predictor of death and myocardial infarction 2012
  • NT-proBNP for risk stratification in atrial fibrillation during treatment with apixaban or warfarin 2012
  • New insight into mental stress induced myocardial ischemia: prevalence and demographic/clinical characteristics 2012
  • Post-operative atrial fibrillation prophylaxis in clinical practice: results from the CAPS-Care STS registry 2012
  • Predictors of augmented peripheral chemosensitivity in patients with systolic heart failure 2012
  • Racial differences in acute aortic dissection: insights from the International Registry of Acute Aortic Dissection 2012
  • Risk of stroke, systemic embolism or death according to heart failure and left ventricular function status in patients with atrial fibrillation: results of the ARISTOTLE trial 2012
  • Unmasked pulmonary venous hypertension during vasodilator challenge predicts poor outcomes with medical therapy 2011
  • Acute renal failure after coronary artery bypass surgery: impact of recovery of renal function on long-term mortality 2010
  • No significant increase in the incidence of infective endocarditis following the cessation of antibiotic prophylaxis for dental procedures 2010
  • Prognostic value of Galectin-3 in chronic heart failure: results from the HF-ACTION Study 2010
  • Saphenous vein grafts with multiple versus single distal targets in patients undergoing coronary artery bypass surgery: one-year graft failure and five-year outcomes from the PREVENT-IV trial 2010
  • A practical, validated model for prediction of risk in chronic heart failure 2006
  • Contraindications to cardiac catheterization in non-ST-elevation acute coronary syndromes: Insights from the CRUSADE national quality improvement initiative 2006
  • Fondaparinux results in less bleeding than enoxaparin, irrespective of heparin use, for patients with acute coronary syndromes 2006
  • Low dose enoxaparin in non-ST segment elevation acute coronary syndrome, followed by antiplatelet therapy alone during subsequent percutaneous coronary intervention 2006
  • Patients with acute ST-elevation myocardial infarction and prehospital delay to presentation > 12 hours: high risk of worse outcomes and selective use of reperfusion therapies. The GRACE registry 2006
  • Racial differences in high-risk patients presenting with NSTE ACS: results from the SYNERGY trial 2006
  • Use of triple and quadruple neurohormonal blockade in heart failure: new data from the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM)-Added trial 2006
  • Analysis of all recurrent events is superior to the time-to-first event in assessment of drug therapy to prevent ICD therapies 2005
  • Atrial fibrillation carries similar risks in heart failure irrespective of ejection fraction-results from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) 2005
  • Bundle branch block is associated with worse clinical outcomes in heart failure, especially with reduced systolic function: evidence from the CHARM programme 2005
  • Deriving a safety index from the GRACE risk score 2005
  • Determinants of delay in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. The Global Registry of acute coronary events 2005
  • Factors precipitating heart failure hospitalisation: a novel analysis of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme 2005
  • Female gender is an independent predictor of better outcome in chronic heart failure: results from the CHARM programme 2005
  • International and time trends in the use and characteristics of patients with acute coronary syndromes treated with clopidogrel: the global registry of acute coronary events experience 2005
  • Intravenous unfractionated heparin, patient profile, and the magnitude of thrombocytopenia are associated with heparin-induced thrombocytopenia (HIT) antibodies: insights from the CATCH registry 2005
  • Predictors of quality of life in symptomatic heart failure patients across the left ventricular ejection fraction spectrum 2005
  • The importance of resting wall motion abnormalities for the diagnostic accuracy of a multicomponent stress CMR test 2005
  • Use of insulin sensitizing agents in outpatients with congestive heart failure appears safe, and may have important clinical benefits when compared with sulfonylureas and insulin 2005
  • Women (especially younger women) with chronic heart failure are less adherent to medication: results from the CHARM program 2005
  • "Leading and lagging" hospitals: can processes of care be used to rank hospitals? 2004
  • Continuous ST-segment recovery analysis is significantly more predictive of mortality than serial static analysis after thrombolytic therapy for acute MI 2004
  • Low haemoglobin is associated with more evidence of congestion but less severe systolic dysfunction in patients with chronic heart failure 2004
  • Substantial reduction in all-cause mortality and morbidity with candesartan in patients with chronic heart failure and systolic left ventricular dysfunction: results of the CHARM low EF trials 2004
  • 2704 Understanding time to treatment in acute myocardial infarction: insights from ASSENT 3 plus 2003
  • 755 Relation of myocardial scarring to clinical risk factors for sudden death in hypertrophic cardiomyopathy 2003
  • P1022 A prospective registry of patients hospitalized for worsening heart failure: observations from the IMPACT-HF registry 2003
  • P1102 Mechanism of pexelizumabs mortality benefit in acute myocardial infarction patients treated with primary percutaneous coronary intervention 2003
  • P1627 Does infarct size measured by creatine kinase-MB predict clinical outcomes after fibrinolysis and primary percutaneous coronary intervention? 2003
  • P2848 Enoxaparin versus unfractionated heparin with tenecteplase in the elderly: combined ASSENT-3 and ASSENT-3 PLUS results 2003
  • P2856 Cumulative meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions 2003
  • P2865 Treating patients with acute coronary syndromes with aggressive anti-platelet agents in the grace registry: no observed decrease in in-hospital mortality but increased bleeding complications 2003
  • P2870 Elective percutaneous coronary intervention using anti-platelet therapy alone, without unfractionated heparin or other anti-thrombin therapy 2003
  • Effect of tenecteplase versus alteplase on platelets in patients during the first three hours after acute myocardial infarction 2002
  • How does ST-segment resolution one-hour after fibrinolysis for acute myocardial infarction predict final infarct size? Insights from ASSENT 3 2002
  • Predictors of in-hospital mortality in the global registry of acute coronary events (GRACE) 2002
  • TNK with reduced dose unfractionated heparin associated with similar efficacy and less bleeding: results from ASSENT-2 and ASSENT-3 2002
  • Conivaptan (CI-1025, YM087), a combined vasopressin V1A/V2 antagonist, reduces pulmonary capillary wedge pressure independent of baseline serum Na or vasopressin levels in heart failure 2001
  • Perspectives gained from large-scale thrombolytic comparative trials. 1996
  • Bleeding risks, risk factors and management of bleeding complications after treatment with anticoagulants, specific antithrombins, thrombolytics IIb-IIIa receptor blockers. 1995
  • Regional left ventricular diastolic properties during pacing induced ischemia in dogs with coronary stenoses 1981